Assessment of the significance of respiratory culture of Aspergillus in the non-neutropenic patient. A critique of published diagnostic criteria

详细信息    查看全文

• 作者：R. C. Barton (1)
  R. P. Hobson (1)
  H. McLoughlin (2)
  A. Morris (1)
  B. Datta (2)
  
• 刊名：European Journal of Clinical Microbiology & Infectious Diseases
• 出版年：2013
• 出版时间：July 2013
• 年：2013
• 卷：32
• 期：7
• 页码：923-928
• 全文大小：157KB
• 参考文献：1. Meersseman W, Van WE (2007) Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med 33:1679-681 p://dx.doi.org/10.1007/s00134-007-0792-y">CrossRef
  2. Ader F (2010) Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: an emerging fungal disease. Curr Infect Dis Rep 12:409-16 p://dx.doi.org/10.1007/s11908-010-0132-1">CrossRef
  3. Bulpa P, Dive A, Sibille Y (2007) Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 30:782-00 p://dx.doi.org/10.1183/09031936.00062206">CrossRef
  4. Bouza E, Guinea J, Pelaez T et al (2005) Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital. J Clin Microbiol 43:2075-079 p://dx.doi.org/10.1128/JCM.43.5.2075-2079.2005">CrossRef
  5. de Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-821 p://dx.doi.org/10.1086/588660">CrossRef
  6. Felton TW, Baxter C, Moore CB et al (2010) Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 51:1383-391 p://dx.doi.org/10.1086/657306">CrossRef
  7. Campbell C, Johnson EM, Philpot C, Warnock DW (1996) Identification of pathogenic fungi. Public Health Laboratory Service, London
  8. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2013. p://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf" class="a-plus-plus">http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf. Accessed 3 January 2013
  9. Denning DW, Riniotis K, Dobrashian R et al (2003) Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 37(Suppl 3):S265–S280 p://dx.doi.org/10.1086/376526">CrossRef
  10. Greenberger PA (2002) Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 110:685-92 p://dx.doi.org/10.1067/mai.2002.130179">CrossRef
  11. Pashley CH, Fairs A, Morley JP et al (2012) Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. Med Mycol 50:433-38 p://dx.doi.org/10.3109/13693786.2011.615762">CrossRef
  12. Mortensen KL, Johansen HK, Fuursted K et al (2011) A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis 30(11):1355-363
  13. Lionakis MS, Kontoyiannis DP (2003) Glucocorticoids and invasive fungal infections. Lancet 362:1828-838 p://dx.doi.org/10.1016/S0140-6736(03)14904-5">CrossRef
  14. Ng TT, Robson GD, Denning DW (1994) Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 140:2475-479 p://dx.doi.org/10.1099/13500872-140-9-2475">CrossRef
  15. O’Donnell MR, Schmidt GM, Tegtmeier BR et al (1994) Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 12:827-34
  16. Peter E, Bakri F, Ball DM et al (2002) Invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy. Clin Infect Dis 35:e54–e56 p://dx.doi.org/10.1086/341971">CrossRef
  17. Leav BA, Fanburg B, Hadley S (2000) Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone. N Engl J Med 343:586 p://dx.doi.org/10.1056/NEJM200008243430818">CrossRef
  18. Guinea J, Torres-Narbona M, Gijon P et al (2010) Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 16:870-77
  19. He H, Ding L, Li F et al (2011) Clinical features of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study. Crit Care 15:R5 p://dx.doi.org/10.1186/cc9402">CrossRef
  20. Bulpa PA, Dive AM, Garrino MG et al (2001) Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med 27:59-7 p://dx.doi.org/10.1007/s001340000768">CrossRef
  21. Denning DW, Lee JY, Hostetler JS et al (1994) NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97:135-44 p://dx.doi.org/10.1016/0002-9343(94)90023-X">CrossRef
  22. Gao X, Chen L, Hu G et al (2010) Invasive pulmonary aspergillosis in acute exacerbation of chronic obstructive pulmonary disease and the diagnostic value of combined serological tests. Ann Saudi Med 30:193-97 p://dx.doi.org/10.4103/0256-4947.62828">CrossRef
  23. Min KH, Park SJ, Kim SR et al (2011) Coexistence of allergic bronchopulmonary aspergillosis and active pulmonary tuberculosis. Am J Respir Crit Care Med 183:137-39 p://dx.doi.org/10.1164/ajrccm.183.1.137">CrossRef
  24. Baxter CG, Bishop P, Low SE et al (2011) Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. Thorax 66:638-40 p://dx.doi.org/10.1136/thx.2010.155515">CrossRef
  25. Chrdle A, Mustakim S, Bright-Thomas RJ et al (2012) Aspergillus bronchitis without significant immunocompromise. Ann NY Acad Sci 1272:73-5 p://dx.doi.org/10.1111/j.1749-6632.2012.06816.x">CrossRef
  
• 作者单位：R. C. Barton (1)
  R. P. Hobson (1)
  H. McLoughlin (2)
  A. Morris (1)
  B. Datta (2)
  
  1. Mycology Reference Centre, Department of Microbiology, Leeds Teaching Hospitals Trust, Leeds, LS1 3EX, UK
  2. Department of Respiratory Medicine, Leeds Teaching Hospitals Trust, Leeds, LS1 3EX, UK
  
• ISSN：1435-4373

文摘

Assessment of the significance of isolation of Aspergillus sp. from respiratory culture in patients who are not neutropenic is a continuing problem in respiratory medicine. In recent years a number of criteria for defining patients with invasive or chronic pulmonary aspergillosis in this group have been proposed. This study sought to assess the value of three sets of these criteria in distinguishing between colonisation and aspergillosis requiring therapy when applied retrospectively to 121 patients with positive sputum or BAL culture for Aspergillus sp. Two patients (1.6?%) were identified as having proven or probable aspergillosis by the EORTC criteria, two different patients fulfilled the criteria for invasive aspergillosis in the 62 patients with chronic obstructive pulmonary disease (3.2?%), and yet another two different patients met the criteria for chronic pulmonary aspergillosis (1.6?%). It is suggested that difficulties in the application of some of these criteria may prevent the accurate diagnosis of aspergillosis in the non-neutropenic patient setting.